Natera (NTRA)
Applies personalized molecular testing across reproductive health, oncology, and organ health.
$391.02
After hours+0.28 (+0.07%)
At close$390.74(+5.42%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 95.62% | 137.83M shares | |
|---|---|---|---|
| 884 holders · as of Jun 30, 2026 | |||
| Insiders | 2.16% | 3.12M shares | |
| 17 holders · as of Sep 18, 2026 | |||
| Other | 2.22% | 3.20M shares | |
| remainder | |||
144.14M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
884 holders · 137.83M shares · 162 new positions · 518 increased · 242 reduced · 77 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| JPMorgan Chase & Co | 12.87M | 8.93% | −521.3K | Aug 12, 2026 |
| BlackRock, Inc. | 10.91M | 7.57% | +237.3K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 9.02M | 6.26% | −3.16M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 6.23M | 4.32% | +219.7K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 5.78M | 4.01% | +137.9K | Aug 13, 2026 |
| FMR LLC | 5.45M | 3.78% | +2.90M | Aug 13, 2026 |
| Wellington Management Group LLP | 4.04M | 2.80% | −727.9K | Aug 14, 2026 |
| State Street Corp | 3.66M | 2.54% | +238.1K | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| JPMorgan Chase & Co. | 9.10% | 12.83M | 13G | Jan 23, 2026 |
| T. Rowe Price Associates, Inc. | 7.80% | 10.87M | 13G | Feb 17, 2026 |
| BlackRock, Inc. | 5.60% | 7.57M | 13G | Apr 17, 2025 |
| Vanguard Capital Management | 5.08% | 7.21M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 16, 2026 | Jonathan Sheenadirector, other: CO-FOUNDER | Sale · 6 lots | 3,150 | $354.19 | 221,314 |
| Sep 15, 2026 | Jonathan Sheenadirector, other: CO-FOUNDER | Sale | 6,000 | $350.07 | 224,464 |
| Sep 15, 2026 | Matthew Rabinowitzdirector, officer: EXECUTIVE CHAIRMAN | Sale · 14 lots | 52,000 | $347.29 | 2,125,394 |
| Sep 14, 2026 | Matthew Rabinowitzdirector, officer: EXECUTIVE CHAIRMAN | Sale · 15 lots | 50,000 | $334.76 | 2,175,394 |
| Sep 11, 2026 | Matthew Rabinowitzdirector, officer: EXECUTIVE CHAIRMAN | Sale · 6 lots | 50,000 | $327.97 | 2,225,394 |
| Sep 2, 2026 | Solomon Moshkevichofficer: PRESIDENT, CLINICALDIAGNOSTICS | Sale | 15,160 | $326.89 | 110,859 |
| Sep 1, 2026 | Solomon Moshkevichofficer: PRESIDENT, CLINICALDIAGNOSTICS | Sale · 3 lots | 3,000 | $320.73 | 126,019 |
| Sep 1, 2026 | Steven Leonard Chapmandirector, officer: CEO AND PRESIDENT | Sale | 1,698 | $320.99 | 98,199 |
| Aug 10, 2026 | John Feskoofficer: PRESIDENT, CHIEF BUS. OFFICER | Sale | 6,517 | $321.53 | 197,257 |
| Aug 10, 2026 | Jonathan Sheenadirector, other: CO-FOUNDER | Sale | 6,000 | $325.32 | 230,464 |
House and Senate disclosures
Not reported.